deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT01438853

Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

The Safety, Pharmacokinetics, and Pharmacodynamic Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

Sponsor: Altor BioScience

Conditions Acute Lung Injury Acute Respiratory Distress Syndrome Sepsis
Interventions Placebo TNX-832
Updated 9 times since 2017 Last updated: Nov 18, 2024 Started: Dec 31, 2004 Primary completion: Jul 31, 2006 Completion: Feb 29, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01438853, this PHASE1 trial focuses on Acute Lung Injury and Acute Respiratory Distress Syndrome and remains completed. Sponsored by Altor BioScience, it has been updated 9 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshotCompleted~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshotCompleted~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE1

  3. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

▶ Show 4 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  2. Sep 2017 — Jun 2018 [monthly]

    Completed PHASE1

  3. Feb 2017 — Sep 2017 [monthly]

    Completed PHASE1

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Altor BioScience
  • Genentech, Inc.
  • Tanox
Data source: Altor BioScience

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations